Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia
- PMID: 7934168
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia
Abstract
The semiautomated fluorometric microculture cytotoxicity assay (FMCA), based on the measurement of fluorescence generated from cellular hydrolysis of fluorescein diacetate (FDA) to fluorescein in microtiter plates, was used for in vitro evaluation of Cladribine (2-chlorodeoxyadenosine, CdA) interactions with five standard antileukemic drugs: amsacrine (Am), etoposide (VP16), daunorubicin (Dnr), cytosine arabinoside (AraC), and mitoxantrone (Mit). Samples from 31 patients with acute myelocytic leukemia (AML) were tested with continuous drug exposure. A large heterogeneity with respect to cell kill was observed for all combinations tested. An additive model provided a significantly better fit of the data compared to the effect of the most active single agent of the combination (Dmax) only for CdA+AraC. When the frequency of additive and synergistic interactions were calculated according to the multiplicative concept for drug interactions, the highest frequencies were observed for CdA+AraC and CdA+Dnr. This interaction pattern was confirmed by isobologram analysis. Cross-resistance analysis revealed high correlations between CdA and AraC whereas the correlations were weaker between CdA and the other drugs. The highest frequency of synergistic interactions was obtained for AraC+CdA, despite their cross-resistance. Of the non-cross-resistant drugs tested, Dnr appears to be the most effective adjunct to CdA in terms of interactions at the cellular level.
Similar articles
-
In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours.Eur J Cancer. 1994;30A(7):1022-6. doi: 10.1016/0959-8049(94)90136-8. Eur J Cancer. 1994. PMID: 7946567
-
Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.Ann Hematol. 2002 Sep;81(9):508-13. doi: 10.1007/s00277-002-0527-7. Epub 2002 Sep 13. Ann Hematol. 2002. PMID: 12373351
-
Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content.Br J Haematol. 2002 Mar;116(3):528-37. doi: 10.1046/j.0007-1048.2001.03300.x. Br J Haematol. 2002. PMID: 11849208
-
On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment.Leuk Lymphoma. 1996 Apr;21(3-4):225-31. doi: 10.3109/10428199209067604. Leuk Lymphoma. 1996. PMID: 8726403 Review.
-
Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies.Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):23-38. doi: 10.2174/157489206775246467. Recent Pat Anticancer Drug Discov. 2006. PMID: 18221024 Review.
Cited by
-
Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.Oncologist. 2020 Nov;25(11):e1663-e1670. doi: 10.1634/theoncologist.2020-0818. Epub 2020 Sep 21. Oncologist. 2020. PMID: 32845551 Free PMC article. Clinical Trial.
-
The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro--from cytotoxic synergy to complete inhibition of apoptosis.Br J Pharmacol. 2002 Oct;137(4):568-73. doi: 10.1038/sj.bjp.0704888. Br J Pharmacol. 2002. PMID: 12359640 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical